UK-based Monument Therapeutics has partnered with the US Foundation for the National Institutes of Health (FNIH) to study ...

Monument Therapeutics, a stratified medicine company, today announced a partnership with the Foundation for the National Institutes of Health (FNIH) to evaluate MT1988, a novel treatment in ...

Monument Therapeutics, a stratified medicine company, today announced a partnership with the Foundation for the National Institutes of Health ...

MT1988 is designed to be used alongside existing anti-psychotic medications for schizophrenia, to address the cognitive symptoms that have long remained untreated.

Cambridge Cognition said on Tuesday that Monument Therapeutics, in which it holds a 20% stake, has partnered with the Foundation for the National Institutes of Health to trial a new treatment for ...

MANCHESTER, England, Nov. 26, 2024 /PRNewswire/ -- Monument Therapeutics, a precision neuroscience company, today announced the first participant has been successfully dosed in its Phase I clinical ...

The clinical trial with MT1988 will be co-led by Dr. Scott Woods and Dr. Youngsun Cho from Yale School of Medicine, Dr. Carrie Bearden from University of California, Los Angeles (UCLA), Dr. John ...

Sheryl Caswell, Chief Development Officer of Monument Therapeutics, added, "The initiation of our Phase I study for MT1988 marks a significant milestone in its clinical development.

Monument Therapeutics announced its partnership with the Foundation for the National Institutes of Health (FNIH) to continue testing and advancing MT1988, a treatment option being developed for ...